AlphAIAlphAI — Financial news for AI agents
prnewswire.com$ATNM

Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models

Actinium Pharmaceuticals (ATNM) presented preclinical results at EANM 2026, showing ATNM-400's potential in lung, colorectal, and ovarian cancer models. The therapy demonstrated tumor growth inhibition and combination benefits, supporting its development as a pan-tumor treatment. ATNM-400 targets HER3, delivering alpha-particle radiation to tumor cells. The company is advancing clinical trials in prostate cancer and exploring further indications.

Original reporting
prnewswire.com
Published Oct 20, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 12:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models — source image
Source · prnewswire.com
Decision brief

The 30-second read

$ATNMBullishMed
01

Why it matters

The data could accelerate ATNM‑400's clinical program and improve valuation.

02

Market read

First disclosure of promising preclinical data for a pipeline candidate, likely to influence ATNM's stock and sector sentiment.

03

What to watch

Potential manufacturing scale‑up challenges and regulatory scrutiny of Actinium‑225 therapies.

Relevance 7/10Novelty 8/10Timing: today

Background

Actinium Pharmaceuticals (NYSE American: ATNM) focuses on Actinium‑225 radioconjugates. The company presented data at the 2026 EANM congress.

Company-level read

Ticker impact

$ATNMBullishHigh confidence
Context

Actinium announced new preclinical data for ATNM-400 showing strong tumor inhibition across lung, colorectal and ovarian cancer models.

Expected impact

upward pressure as the market prices in potential clinical success

Evidence & confidence

First disclosure of robust preclinical data; could accelerate clinical timelines and attract funding.

Market effects

Sector

Strengthens the targeted radiotherapy and alpha‑particle therapy sector, may lift peers developing HER3‑targeted agents.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Highlights growing interest in radiopharmaceuticals worldwide.

Counterpoint

What could challenge this read

Preclinical success does not guarantee clinical efficacy; investors may remain cautious until human data.

Key entities

  • Company
    Actinium Pharmaceuticals

    Developer of ATNM‑400, a HER3‑targeted alpha‑particle radioconjugate.

Read at source← All news

StoryActinium reports broad ATNM-400 activity in cancer models at EANM 2026

Also covered by

2 outlets

Related articles

$ATNMMed

Actinium begins enrolling patients in RADIANZ imaging trial

Actinium Pharmaceuticals (ATNM) has started patient enrollment in its RADIANZ imaging trial. The study will evaluate ⁸⁹Zr-Barecetamab-DFO using PET imaging to guide development of ATNM-400 in solid tumors. It includes patients with non-small cell lung, breast, colorectal, pancreatic, and ovarian cancers. The trial follows initial results from a Phase 1 study in prostate cancer, showing no dose-limiting toxicities.

investing.com
$ATNMMed

Actinium Pharmaceuticals Announces Enrollment in the RADIANZ Imaging Clinical Trial Intended to Demonstrate the Pan-Cancer Potential of ATNM-400, A First-in-Class HER3-Targeting Radiotherapy

Actinium Pharmaceuticals (ATNM) has begun enrolling patients in the RADIANZ clinical trial for ATNM-400, a HER3-targeting radiotherapy. The study aims to expand ATNM-400's potential beyond prostate cancer to other solid tumors. Initial data in prostate cancer showed tumor uptake and no dose-limiting toxicities. The company plans to present additional breast cancer data at the San Antonio Breast Cancer Symposium.

prnewswire.com
$ATNMMedAI 8/10

Actinium Pharmaceuticals Announces Three ASH 2026 Abstracts Highlighting Iomab-ACT Clinical Results in CAR T-Cell Therapy and Sickle Cell Disease

Actinium Pharmaceuticals (ATNM) announced three abstracts for ASH 2026, highlighting Iomab-ACT's potential in CAR T-cell therapy and sickle cell disease. The studies explore Iomab-ACT as a conditioning agent before cellular therapies, reducing reliance on chemotherapy. According to the company, the results support Iomab-ACT's development as a universal targeted conditioning regimen.

prnewswire.com
$ATNMMedAI 8/10

Actinium Pharmaceuticals Announces ASH 2026 Abstract Highlighting Long-Term Results of Actimab-A in Combination with CLAG-M in Relapsed or Refractory AML

Actinium Pharmaceuticals (ATNM) announced long-term safety results of Actimab-A combined with CLAG-M for relapsed/refractory AML at ASH 2026. The study showed potential for bone marrow recovery and addressed kidney/liver toxicities. Prior data showed 1- and 2-year survival rates of 59% and 32% in venetoclax-failed patients, and 51% and 19% in TP53-mutated AML patients. Actinium aims to develop Actimab-A as a mutation-agnostic AML treatment.

prnewswire.com
$ATNMMed

Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026

Actinium Pharmaceuticals (ATNM) announced its first-in-human Phase 1 study of ATNM-400, a HER3-targeted radiotherapy for metastatic castration-resistant prostate cancer, will be presented at ESMO 2026. The study evaluates safety, dosing, and antitumor activity, with potential to address treatment resistance across multiple solid tumors. ATNM-400 targets HER3, distinct from PSMA, and is designed to deliver Actinium-225 to tumor cells.

prnewswire.com